Lonza Group Signs Definitive Agreement to Acquire Contract Development, Manufacturing Sites
MT Newswires11-03
Lonza Group (SGX:O6Z) has signed a definitive agreement to acquire five contract development and manufacturing sites in the US from Merck KGaA, according to a Tuesday filing with the Singapore Exchange.
The pharmaceutical company is expected to pay a total enterprise valuation in the low to mid triple-digit millions of Swiss francs, with the transaction funded from cash at hand and existing credit facilities.
The deal will add around 1,100 employees and lifts the company's US-based CDMO sites to nine.
The company is forecasting around 250 million francs in sales in 2028 at core EBITDAA margin below Lonza's from the acquired sites.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
